Vasculostatic agents and methods of use thereof

• US 20050282814A1
• Filed: 04/13/2005
• Published: 12/22/2005
• Est. Priority Date: 10/03/2002
• Status: Abandoned Application

• Current Assignee: TargeGen, Inc. (Sanofi )
• Original Assignee: TargeGen, Inc. (Sanofi )
• Inventors: Dneprovskaia, Elena, Gong, Xianchang, Hood, John D., Noronha, Glenn, Zhao, Ningning, Splittgerber, Ute, Wrasidlo, Wolfgang, Doukas, John, Royston, Ivor
• Application Number:
  US11/105,845
• Publication Number:
  US 20050282814A1
• Time in Patent Office: Days
• US Class Current: 514/251
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/724 Cyclodextrins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07D 209/14 Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• CPC Class Codes: C07D 209/48 with oxygen atoms in positions 1 and 3, e.g. phthalimide
• CPC Class Codes: C07D 239/88 Oxygen atoms
• CPC Class Codes: C07D 239/90 with acyclic radicals attached in position 2 or 3
• CPC Class Codes: C07D 239/95 with hetero atoms directly attached in positions 2 and 4
• CPC Class Codes: C07D 241/42 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• CPC Class Codes: C07D 253/10 Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/04 : Ortho-condensed systems

Abstract

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

Claims

1. A method for treating a disorder associated with compromised vasculostasis, comprising administering to a subject in need thereof an effective amount of a compound having the general structure (III), or a pharmaceutically acceptable salt, hydrate, solvate, crystal form or individual diastereomers thereof:

wherein;

each of Z₁-Z₆ is, independently, C, —

C═

O, N, or NR^a, wherein R^a is —

H, alkyl, or substituted alkyl, wherein the substituents in the substituted alkyl are halogen, hydroxy, oxo, or amino;

each X is independently halogen, —

OR^b, —

NR^b₂, or —

SR^b, wherein R^b is —

H, lower alkyl, —

(CH₂)₂NH(CH₂CH₃), —

(CH₂)₃morpholyn-1-yl, —

(CH₂)₃(N-methylpiperazinyn-1-yl), aryl, heteroaryl, —

(NH—

NH—

R^c), —

(N═

N—

NH—

R^c), wherein R^c is H or lower alkyl;

each Y is independently —

OR^d, —

NR^d₂, —

SR^d, or —

OPO₃H₂, wherein R^d is H, lower alkyl, aryl, heteroaryl, —

(CH₂)₂NH(CH₂CH₃), —

(CH₂)₃morpholyn-1-yl, or —

(CH₂)₃(N-methyl piperazinyn-1-yl);

or each Y is independently alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or halogen, wherein said substituents are selected from halogen, —

OR^e, —

NR^e₂, —

SR^e, —

P(O)(OH)₂, wherein R^e is —

H, lower alkyl, aryl, or heteroaryl;

or each Y is independently CH₂glycinyl, CH₂NHethoxy, CH₂NHCH₂alkyl, CH₂NHCH₂t-Bu, CH₂NHCH₂aryl, CH₂NHCH₂substituted aryl, CH₂NHCH₂heteroaryl, CH₂NHCH₂substituted heteroaryl;

or when n is 2, each Y is taken together to form a fused aromatic or heteroaromatic ring system; and

each of m and n is, independently, an integer having the value between 1 and 4,

wherein when Z₁, Z₃, Z₅, and Z₆ are each N, X is NH₂, and m=n=2, Y is not phenyl or 4-hydroxyphenyl, or tautomers thereof, thereby treating the subject.

2. The method of claim 1, wherein the compound of the general structure (III) has the formula (III-A):

wherein;

each X is independently H, halogen, OR, NR₂, or SR, wherein R is H, aryl, substituted aryl, or lower alkyl;

each Y is independently hydrogen, alkyl, substituted alkyl, alkenyl substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, or substituted acyl, with the proviso that at least one Y is not hydrogen, or when n is 2, each Y is taken together to form a fused aromatic ring system comprising at least one aromatic ring; and

each of m and n are is, independently, 1 or 2.

3. The method of claim 1, wherein the compound of the general structure (III) has the formula (IIIb):

4. The method of any one of claims 1-3, wherein the disorder is myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, cancer, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, autoimmune disease, vascular leakage syndrome, inflammatory disease, edema, transplant rejection, burn, or acute or adult respiratory distress syndrome (ARDS).

5. The method of claim 4, wherein the disorder is vascular leakage syndrome (VLS).

6. The method of claim 4, wherein the disorder is cancer.

7. The method of claim 4, wherein the disorder is a vitreoretinal disease.

8. The method of claim 4, wherein the disorder is ARDS.

9. The method of claim 4, wherein the disorder is autoimmune disease.

10. The method of claim 4, wherein the disorder is burn.

11. The method of claim 4, wherein the disorder is stroke.

12. The method of claim 4, wherein the disorder is myocardial infarction.

13. The method of claim 4, wherein the disorder is ischemia or reperfusion injury.

14. The method of claim 4, wherein the disorder is arthritis.

15. The method of claim 4, wherein the disorder is edema.

16. The method of claim 4, wherein the disorder is transplant rejection.

17. The method of claim 4, wherein the disorder is inflammatory disease.

18. The method of claim 4, wherein the disorder is congestive heart failure.

19. A method of treating a disorder associated with compromised vasculostasis comprising the administration of a therapeutically effective amount of at least one compound as set forth in Structures III, IIIa, or IIIb, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers thereof, in combination with an anti-inflammatory agent, a therapeutic agent, a chemotherapeutic agent, a PI3K inhibitor, an immunomodulatory agent, a therapeutic antibody or a protein kinase inhibitor, to a subject in need of such treatment, thereby treating the subject.

20. The method of claim 19, wherein the kinase is a Src family kinase.

21. The method of claim 19, wherein the protein kinase inhibitor a VEGF inhibitor.

22. The method of claim 19, wherein the disorder is myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, cancer, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, autoimmune disease, vascular leakage syndrome, inflammatory disease, edema, transplant rejection, burn, or acute or adult respiratory distress syndrome (ARDS).

23. The method of claim 19, wherein the disorder is vascular leakage syndrome (VLS).

24. The method of claim 19, wherein the disorder is cancer.

25. The method of claim 19, wherein the disorder is a vitreoretinal disease.

26. The method of claim 19, wherein the disorder is ARDS.

27. The method of claim 19, wherein the disorder is autoimmune disease.

28. The method of claim 19, wherein the disorder is burn.

29. The method of claim 19, wherein the disorder is stroke.

30. The method of claim 19, wherein the disorder is myocardial infarction.

31. The method of claim 19, wherein the disorder is ischemia or reperfusion injury.

32. The method of claim 19, wherein the disorder is arthritis.

33. The method of claim 19, wherein the disorder is edema.

34. The method of claim 19, wherein the disorder is transplant rejection.

35. The method of claim 19, wherein the disorder is inflammatory disease.

36. The method of claim 19, wherein the disorder is congestive heart failure.

37. The method of claim 22, wherein the cancer is an alimentary/gastrointestinal tract cancer, colon cancer, liver cancer, skin cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer or brain cancer.

38. The method of claim 37, wherein the cancer is colon cancer or lung cancer.

39. The method of claim 19, wherein the therapeutic agent is an antimetabolite;

a DNA cross-linking agent;

alkylating agent;

topoisomerase I inhibitor;

microtubule inhibitors, a vinca alkaloid, mitomycin-type antibiotic, and a bleomycin-type antibiotic.

40. The method of claim 19, wherein the therapeutic agent is an antibody that binds to HER2 protein, growth factors or growth factor receptors, or integrin receptors.

41. The method of claim 19, wherein the chemotherapeutic agent is methotrexate, cisplatin/carboplatin;

canbusil;

dactinomicin;

taxol (paclitaxol), antifolate, colchicine, demecoline, etoposide, taxane/taxol, docetaxel, doxorubicin, anthracycline antibiotic, doxorubicin, daunorubicin, carminomycin, epirubicin, idarubicin, mithoxanthrone, 4-demethoxy-daunomycin, 11-deoxydaunorubicin, 13-deoxydaunorubicin, adriamycin-14-benzoate, adriamycin-14-octanoate, adriamycin-14-naphthaleneacetate, trastuzumab, bevacizumab, OSI-774, or Vitaxin.

42. The method of claim 41, wherein the chemotherapeutic agent is doxorubicin, docetaxol, or taxol.

43. A method for inhibiting or reducing vascular leakage in a subject, comprising administering to a subject in need thereof an effective amount of IL-2 in combination with a a therapeutically effective amount of at least one compound as set forth in Structures III, IIIa, or IIIb, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers thereof, thereby reducing vascular leakage in the subject.

44. The method of claim 43, wherein the compound is 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine.

45. A method of treating acute myocardial infarction, comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of phosphoinositide-3-kinase, thereby treating the subject.

46. The method of claim 45, wherein the inhibitor of phosphoinositide-3-kinase is administered in combination with a compound selected from a group consisiting of an anti-inflammatory agent, a therapeutic agent, a chemotherapeutic agent, an immunomodulatory agent, a therapeutic antibody, and a combination thereof.

47. The method of claim 46, wherein the therapeutic agent is an antimetabolite;

a DNA cross-linking agent;

alkylating agent;

topoisomerase I inhibitor;

microtubule inhibitors, a vinca alkaloid, mitomycin-type antibiotic, and a bleomycin-type antibiotic.

48. The method of claim 46, wherein the chemotherapeutic agent is methotrexate, cisplatin/carboplatin;

canbusil;

dactinomicin;

taxol (paclitaxel), antifolate, colchicine, demecoline, etoposide, taxane/taxol, docetaxel, vatalenib, doxorubicin, anthracycline antibiotic, doxorubicin, daunorubicin, carminomycin, epirubicin, idarubicin, mithoxanthrone, 4-demethoxy-daunomycin, 11-deoxydaunorubicin, 13-deoxydaunorubicin, adriamycin-14-benzoate, adriamycin-14-octanoate, adriamycin-14-naphthaleneacetate, trastuzumab, bevacizumab, OSI-774, or Vitaxin.

49. The method of claim 48, wherein the chemotherapeutic agent is doxorubicin, docetaxel, or taxol.

50. The method of claim 45, wherein the inhibitor is selected from a compound as set forth in Structures III, IIIa, or IIIb, or any combination thereof.

51. The method of claim 48, wherein the chemotherapeutic agent is administered in a range of IC50 of less than 1 μ

M.

52. The method of claim 45, wherein the inhibitor is LY294002.

53. A pharmaceutical composition, comprising 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine, or a pharmceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

54. The pharmaceutical composition of claim 53, further comprising cyclodextrin.

55. The pharmaceutical composition of claim 54, wherein cyclodextrin is β

-cyclodextrin or a derivative thereof.

56. The pharmaceutical composition of claim 55, wherein the derivative of β

-cyclodextrin is sulfobutyl ether.

57. The pharmaceutical composition of claim 54, wherein the molar ratio between 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine and cyclodextrin is between about 0.2 and 5.

58. The pharmaceutical composition of claim 54, wherein the molar ratio between 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine and cyclodextrin is between about 0.5 and 4.

59. The pharmaceutical composition of claim 54, wherein the molar ratio between 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine and cyclodextrin is between about 0.7 and 3.6.

60. The pharmaceutical composition of claim 54, further comprising citric acid.

61. The pharmaceutical composition of claim 60, wherein the concentration of 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine is about 23 mg/ml.

62. A pharmaceutical composition, comprising 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine and sulfobutyl ether β

-cyclodextrin, wherein the concentration of 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine is 23 mg/ml and the concentration of sulfobutyl ether β

-cyclodextrin is 16% by mass.

63. A pharmaceutical composition, comprising:

(a) about 540.2 g 6,7-bis-(3-hydroxyphenyl)-pteridine-2,4-diamine;

(b) about 3,680 g a sulfobutyl ether derivative of β

-cyclodextrin;

(c) about 82.1 g citric acid; and

(d) about 21,595 g sterile water for injection.